FDA Extends Compliance Dates for Drug Dispensers

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-11-04-2015
Volume 11
Issue 11

Citing compliance issues, FDA extends deadline for product tracing information requirements for dispensers to March 1, 2016.

FDA has issued a revised guidance document that extends a previously issued Compliance Policy for the Drug Supply Chain Security Act (DSCSA) from Nov. 1, 2015 to March 1, 2016 because some drug dispensers-primarily smaller, independent pharmacies and health systems-have expressed that they need additional time to work with partners on compliance issues.  

The DSCSA requires dispensers, primarily pharmacies, to comply with new requirements related to product tracing beginning July 1, 2015. In a Compliance Policy published on July 6, 2015, FDA stated that the agency did not intend to take action until Nov. 1, 2015 against dispensers that accepted ownership of product without receiving the product tracing information or who did not capture and maintain the product tracing information as required by the law. 

The most recent FDA guidance document, DSCSA Implementation: Product Tracing Requirements for Dispensers–Compliance Policy (Revised), issued on Oct. 28, 2015, extends this compliance date to March 1, 2016. FDA notes that the compliance policy does not extend to other requirements of the Federal Food, Drug, and Cosmetic Act, including those in section 582, such as verification related to suspect and illegitimate product (including quarantine, investigation, notification and recordkeeping) and requirements related to engaging in transactions only with authorized trading partners.

The guidance document is available on the FDA website.

Source:  US Food and Drug Administration

 

 

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content